The Conversation (2)
The Financial Times reported that a research partnership involving Boston’s Northeastern University, the University of Bonn and NovoBiotic Pharmaceuticals LLC has announced a new antibiotic that bacteria likely won’t become resistant to for several decades.
The Financial Times reported that a research partnership involving Boston’s Northeastern University, the University of Bonn and NovoBiotic Pharmaceuticals LLC has announced a new antibiotic that bacteria likely won’t become resistant to for several decades.
As quoted in the market news:
The drug, called teixobactin, quickly cleared infections in animal tests without side effects.
Although it is at least two years from clinical trials and five years from commercial availability, microbiologists hailed teixobactin as an exciting discovery at a time when politicians and public health leaders worldwide are flagging up the urgent need for drugs to tackle the problem of antibiotic resistance. Details are published in the journal Nature.